Tesaro's ovarian cancer drug gets EU agency backing
(Reuters) - A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Health | Ovarian Cancer | Ovaries